Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.061 AUD | +1.67% | +1.67% | -14.08% |
Apr. 04 | Noxopharm Receives AU$100,000 to Progress Brain Cancer Drug | MT |
Feb. 27 | Noxopharm Narrows Fiscal H1 Net Loss Despite Lower R&D Tax Incentive | MT |
Sales 2022 | 5.43M 3.54M | Sales 2023 | 6.01M 3.92M | Capitalization | 12.57M 8.19M |
---|---|---|---|---|---|
Net income 2022 | -18M -11.73M | Net income 2023 | -15M -9.78M | EV / Sales 2022 | 7.95 x |
Net cash position 2022 | 13.85M 9.03M | Net cash position 2023 | 3.01M 1.96M | EV / Sales 2023 | 1.59 x |
P/E ratio 2022 |
-3.04
x | P/E ratio 2023 |
-0.83
x | Employees | - |
Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 64.79% |
1 day | +1.67% | ||
1 week | +1.67% | ||
Current month | -8.96% | ||
1 month | -14.08% | ||
3 months | -21.79% | ||
6 months | -39.00% | ||
Current year | -14.08% |
Managers | Title | Age | Since |
---|---|---|---|
Gisela Mautner
CEO | Chief Executive Officer | - | - |
Director of Finance/CFO | - | 19-02-28 | |
Olivier Laczka
CTO | Chief Tech/Sci/R&D Officer | - | 19-10-15 |
Members of the board | Title | Age | Since |
---|---|---|---|
Fred Bart
CHM | Chairman | 69 | 20-05-07 |
Peter Marks
BRD | Director/Board Member | 68 | 16-03-14 |
Boris Patkin
BRD | Director/Board Member | - | 20-03-25 |
Date | Price | Change | Volume |
---|---|---|---|
24-04-22 | 0.061 | +1.67% | 15,505 |
24-04-19 | 0.06 | -3.23% | 215,468 |
24-04-18 | 0.062 | +3.33% | 12,401 |
24-04-17 | 0.06 | -5.51% | 486,889 |
Delayed Quote Australian S.E., April 22, 2024 at 02:10 am EDT
More quotes1st Jan change | Capi. | |
---|---|---|
-14.08% | 11.57M | |
-2.86% | 87.31B | |
+2.63% | 40.86B | |
-21.53% | 29.36B | |
+58.56% | 24.49B | |
-13.74% | 17.31B | |
-18.52% | 11.62B | |
-15.61% | 11.31B | |
-44.02% | 11.26B | |
+5.17% | 8.31B |
- Stock Market
- Equities
- NOX Stock